Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 5,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Lung Cancer Clear all

Conditions: Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
Interventions: upifitamab rilsodotin; Drug
Lead sponsor: Mersana Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Malignant Mesothelioma
Interventions: Cisplatin, Methotrexate, Vinorelbine ditartrate, Adjuvant therapy, Conventional surgery, Neoadjuvant Therapy, 3-dimensional conformal radiation therapy, Intensity-modulated radiation therapy; Drug · Procedure · Radiation
Lead sponsor: The Cleveland Clinic; Other
Eligibility: Up to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Lung Cancer
Interventions: indium In 111 monoclonal antibody MN-14, yttrium Y 90 monoclonal antibody MN-14; Radiation
Lead sponsor: Garden State Cancer Center at the Center for Molecular Medicine and Immunology; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Belleville, New Jersey

Conditions: Insomnia
Interventions: Assisted Relaxation Therapy, Modified Assisted Relaxation Therapy; Behavioral
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Usual Care, Intervention Arm; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 10
States / cities: Lewes, Delaware • Savannah, Georgia • Chicago, Illinois + 7 more

Conditions: Non-small Cell Lung Cancer Stage I
Interventions: Ad5-yCD/mutTKSR39rep-ADP Adenovirus; Biological
Lead sponsor: Benjamin Movsas, M.D.; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: High-grade Glioma, Lung Cancer, Head & Neck Cancer, Sarcoma, Melanoma
Interventions: Fluciclatide Injection - (AH111585 (F18)); Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Lung Cancer
Interventions: Erlotinib (Tarceva); Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Advanced Solid Tumors
Interventions: BAY2416964; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 4
States / cities: New Haven, Connecticut • Greenville, South Carolina • Houston, Texas + 1 more

Conditions: Non-Small Cell Lung Cancer
Interventions: RAD001 (in addition to standard radiation and chemotherapy); Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 89 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
Interventions: ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Trastuzumab emtansine; Drug
Lead sponsor: Enliven Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Aurora, Colorado • Orlando, Florida • Plantation, Florida + 2 more

Conditions: Non-small Cell Lung Cancer
Interventions: Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo; Biological · Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 1,513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 49
States / cities: Fort Smith, Arkansas • Anaheim, California • Glendale, California + 41 more

Conditions: COPD, Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy, Idiopathic Pulmonary Fibrosis, Other Interstitial Lung Disease Without Curative Therapy, Congestive Heart Failure, NYHA Class IV or NYHA Class III Plus 1 Hospitalization in the Past Year, Malignancy, Any Stage 3B or 4 Solid Tumor
Interventions: Comfort Default AD forms, Life Extension Default AD forms, Standard Default AD forms; Other
Lead sponsor: Corporal Michael J. Crescenz VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Early Stage Non-Small Cell Lung Cancer
Interventions: Avelumab, SBRT; Drug · Radiation
Lead sponsor: Andrew Sharabi; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: La Jolla, California • Sioux Falls, South Dakota

Conditions: Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, Melanoma, Non-small Cell Lung Cancer
Interventions: Synthetic long peptide personalized cancer vaccine, Poly ICLC, Signatera or Altera testing; Biological · Drug · Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 3
States / cities: Orlando, Florida • St Louis, Missouri • Columbus, Ohio

Conditions: Lung Cancer
Interventions: cisplatin, pemetrexed disodium, adjuvant therapy, conventional surgery, neoadjuvant therapy; Drug · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
Interventions: filgrastim, amifostine trihydrate, cisplatin, etoposide, paclitaxel, topotecan hydrochloride, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 84
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 51 more

Conditions: Resectable Lung Non-Small Cell Carcinoma
Interventions: Biospecimen Collection, Proton Beam Radiation Therapy, Radiology, Treatment Planning; Procedure · Radiation · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Non Small Cell Lung Cancer
Interventions: IPI 504 plus Docetaxel, Placebo plus Docetaxel; Drug
Lead sponsor: Infinity Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 41
States / cities: Chandler, Arizona • Tucson, Arizona • Orange, California + 38 more

Conditions: Stage IV Lung Cancer
Interventions: Antineoplaston therapy (Atengenal + Astugenal); Drug
Lead sponsor: Burzynski Research Institute; Other
Eligibility: 18 Years to 99 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2000
U.S. locations: 1
States / cities: Houston, Texas

Conditions: COVID-19 Infection
Interventions: Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-small Cell Lung Cancer
Interventions: Non-ablative SBRT; Radiation
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Malignant Mesothelioma
Interventions: pemetrexed disodium, clinical observation; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 145
States / cities: Scottsdale, Arizona • San Francisco, California • Hartford, Connecticut + 104 more

Conditions: Non-small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatocellular Carcinoma (HCC)
Interventions: Copanlisib, Nivolumab; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Beverly Hills, California • Los Angeles, California • Denver, Colorado + 2 more

Search by objective public record fields.

First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b

Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma

Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Behavioral Relaxation Approaches for Insomnia in Lung Cancer Patients

Improving Resection Rates Among African Americans With NSCLC

Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer

A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis

A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer

A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer

Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

Study of Default Options in Advance Directives

SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer

A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer

Assessment of the Psychosocial Impact of the COVID-19 Pandemic on the MD Anderson Cancer Center Workforce

Pre-Operative Immuno-Modulatory SBRT (POIMS Trial): A Pilot Trial in Early Stage NSCLC

Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy

An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors